Ramelteon: Research, Dosing, and Where to Buy in 2026
A research-first profile for Ramelteon (ramelteon, Rozerem), aggregating mechanism notes, transcript dosing mentions, vendor recommendations, and PubMed-indexed literature without presenting medical guidance.
Ramelteon is a research compound profiled here from named-expert transcripts and peer-reviewed literature, without medical guidance. As of July 2026, The Peptide Wiki aggregates 8 PubMed-cited papers, and 1 attributed expert mention for Ramelteon, each linked to its source.
- Also indexed as ramelteon, Rozerem.
- 0 aggregated dosing-protocol mentions from source transcripts.
- 8 PubMed-indexed citations listed in the research table below.
- 0 vendor recommendations captured from named experts.
What is Ramelteon?
Research compound aggregated from creator and literature mentions. No direct disease-treatment claims are made on this page.
Experts on background and overview · 1 cited mention
"ramelteon, also known as Rozerem, which is a melatonin receptor agonist, which is metabolized differently. So, if you don't respond well to melatonin sublingually or orally or in slow and immediate release, then look into ramelteon Rozerem."
Ramelteon Dosing Protocols
The entries below are transcript-derived dosing mentions. They are preserved for research context and are not medical advice.
No transcript-derived dosing mentions in current source set.
Where to Buy Ramelteon in 2026
No tracked vendor recommendations for Ramelteon yet. See our vendor directory.
Side Effects and Safety
Anecdotal reports and study-level observations vary by route, dose, and individual. This page does not provide medical advice. Consult a qualified clinician before any research use.
What Experts Say
1 expert across our source library discuss Ramelteon. Each entry is that expert’s most context-rich mention: click to watch it at the exact timestamp in the original video. Quotes are also emitted as Schema.org Quotation JSON-LD for AI assistants.
-
“ramelteon, also known as Rozerem, which is a melatonin receptor agonist, which is metabolized differently. So, if you don't respond well to melatonin sublingually or orally or in slow and...”
User Reviews
User reviews aggregator coming Q3 2026 (Reddit + YouTube comments + Discord research notes). Until then, see the expert quote section above and PubMed citations below.
Research Efficacy Snapshot
Published efficacy percentages cited in PubMed trials and named-expert reports about Ramelteon. Each line links to the original source.
- "Random-effects meta-analysis pooled risk ratios (RRs) and median differences with 95% CIs." · de Oliveira H et al, 2025 PubMed
- "Twenty-four studies involving 4489 patients were analyzed, of whom 1752 (39%) received one of the evaluated pharmacotherapies." · de Oliveira H et al, 2025 PubMed
- "Pooled analyses showed a significant reduction in delirium prevalence in both randomized trials (RR, 0.60; 95% CI, 0.38-0.97; low certainty) and observational studies (RR, 0.54; 95% CI, 0.43-0.68; low certainty)." · de Oliveira H et al, 2025 PubMed
- "Sleep-wake regulating pharmacologic agents were associated with 40%-46% relative risk reductions in delirium prevalence, based on low-certainty evidence." · de Oliveira H et al, 2025 PubMed
- "For the subgroup mean age of patients ≥55, PR melatonin was efficacious on oSE with a large effect size (p < 0.001; weighted difference = 2.95%)." · Maruani J et al, 2023 PubMed
- "A trial sequential analysis was performed using relative risk reduction thresholds of 50%." · Yu C et al, 2023 PubMed
- "The primary outcome was the incidence of delirium (reported as odds ratio with 95% confidence intervals)." · Yu C et al, 2023 PubMed
- "This updated meta-analysis showed that ramelteon was associated with lower odds of delirium occurrence than placebo (0.50; 0.29-0.86; I2  = 17.48%)." · Yu C et al, 2023 PubMed
- "In trial sequential analysis, the effect of ramelteon across the superiority boundary when using a relative risk reduction threshold ranging from 40% to 60%." · Yu C et al, 2023 PubMed
- "Intermediate-acting benzodiazepines, long-acting benzodiazepines, and eszopiclone had fewer discontinuations due to any cause than ramelteon (OR 0·72 [95% CI 0·52-0·99; moderate], 0·70 [0·51-0·95; moderate] and 0·71 [0·52-0·98; moderate], respectively)." · De Crescenzo F et al, 2022 PubMed
Research and Studies
8 PubMed-indexed papers reference Ramelteon. Top 8 shown.
Legal Status
Ramelteon is presented here as a research compound. FDA approval status, scheduling, WADA status, and state-specific telehealth rules may apply. Always verify current regulatory status. Last verified: 2026-07-09.
Frequently Asked Questions
Is Ramelteon FDA-approved?
Ramelteon is presented on this page as a research compound. FDA approval status, scheduling, and state-specific rules may apply and change. Verify current regulatory status before any decision.
How much research has been published on Ramelteon?
8 PubMed-indexed paper(s) reference Ramelteon in our current research feed. See the Research and Studies section above for citations.